# US 2012/0237514 A1 · Vascular endothelial cell growth factor antagonists and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0237514 A1
- Document ID: US20120237514A1
- Status: Published application
- Kind: A1
- Application number: 13/485,827
- Filed: 2012-05-31
- Published: 2012-09-20
- Earliest claimed: 1998-12-22
- Assignees: Genentech, Inc.
- Inventors: Nicholas Van Bruggen; Napoleone Ferrara
- Web page: https://patentgrep.com/patent/US20120237514A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 39/39533: {against materials from animals}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/18: against material from animals or humans
- C07K 16/24: against cytokines, lymphokines or interferons
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.

## Claims

### Claim 1

A method of treating a mammal having edema comprising administering to said mammal an effective amount of hVEGF antagonist, wherein said hVEGF antagonist comprises an hVEGF receptor fusion protein.

### Claim 2 (depends on 1)

The method of claim 1 wherein said edema comprises cerebral edema.

### Claim at position 3

-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1 wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.

### Claim 13 (depends on 12)

The method of claim 12 wherein said hVEGF receptor fusion protein comprises a flt-IgG fusion protein.

### Claim 14

A method of treating a mammal having or having undergone a stroke, comprising administering to said mammal an effective amount of hVEGF antagonist, wherein said hVEGF antagonist comprises an hVEGF receptor fusion protein.

### Claim at position 7

-19. (canceled)

### Claim 20 (depends on 14)

The method of claim 14 wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.

### Claim 21 (depends on 20)

The method of claim 20 wherein said hVEGF receptor fusion protein comprises a flt-IgG fusion protein.

### Claim at position 10

-29. (canceled)

### Claim 30

A method of reducing cerebral edema due to a non-neoplastic condition in a mammal, comprising administering to said mammal a hVEGF antagonist in an amount effective to reduce the volume of cerebral edema, wherein said hVEGF antagonist comprises an hVEGF receptor fusion protein.

### Claim 31 (depends on 30)

The method of claim 30, wherein the non-neoplastic condition comprises head injury, spinal cord injury, acute hypertension, meningitis, encephalitis, abscess, hemorrhage, viral infection, cerebral malaria, radiation, multiple sclerosis, cardiac arrest, birth asphyxia, glutamate toxicity, encephalopathy, hypoxia, ischemia, or renal dialysis.

### Claim at position 13

-36. (canceled)

### Claim 37 (depends on 30)

The method of claim 30, wherein said hVEGF receptor fusion protein comprises an extracellular domain sequence of a hVEGF receptor fused to an immunoglobulin.

### Claim 38 (depends on 37)

The method of claim 37, wherein the hVEGF receptor fusion protein comprises a flt-IgG fusion protein.

### Claim 39 (depends on 1)

The method of claim 1 wherein the hVEGF receptor fusion protein comprises a truncated form of an hVEGF receptor.

### Claim 40 (depends on 39)

The method of claim 39 wherein the transmembrane and the cytoplasmic domains of a hVEGF receptor are not present in the truncated form of the hVEGF receptor.

### Claim 41 (depends on 1)

The method of claim 1 wherein the hVEGF receptor fusion protein comprises a hVEGF receptor or fragment thereof conjugated to a non-hVEGF receptor polymer or polypeptide.

### Claim 42 (depends on 41)

The method of claim 41 wherein non-hVEGF receptor polymer or polypeptide is an immunoglobulin or fragment thereof.

### Claim 43 (depends on 42)

The method of claim 42 wherein the fragment of the immunoglobulin comprises an Fv domain, a CH1 domain, a CH2 domain, or a hinge region between the CH1 and CH2 domains.

### Claim 44 (depends on 43)

The method of claim 43 wherein the Fv domain is located in an extracellular domain of the hVEGF fusion protein.

### Claim 45 (depends on 43)

The method of claim 43 wherein the N-terminus of the CH1 domain, CH2 domain, or hinge region between the CH1 and CH2 domains is covalently joined to the C-terminus of an extracellular domain of the VEGF receptor fusion protein.
